Amato, P. G., Ponziani G, Siracusa G, Fratiglioni L, Amaducci L (1993). "Longterm safety of azathioprine therapy in multiple sclerosis." Neurology 43: 831 - 833.
Beck, R. W., P. A. Cleary, et al. (1992). "A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group." N Engl J Med 326(9): 581-588.
Bornstein, M. B., A. Miller, et al. (1987). "A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis." N Engl J Med 317(7): 408-414.
Bruck, W. and C. Stadelmann (2003). "Inflammation and degeneration in multiple sclerosis." Neurol Sci 24 Suppl 5: S265-267.
Casetta, I., G. Iuliano, et al. (2007). "Azathioprine for multiple sclerosis." Cochrane Database Syst Rev(4): CD003982.
Chaplain, G., C. Milan, et al. (2000). "Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study." J Clin Oncol 18(15): 2836-2842.
Charles, C., A. Gafni, et al. (1997). "Shared decision-making in the medical
encounter: what does it mean? (or it takes at least two to tango)." Soc Sci Med 44(5): 681-692.
Charles, C., A. Gafni, et al. (1999). "Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model." Soc Sci Med 49(5): 651-661.
Charles, C., T. Whelan, et al. (1999). "What do we mean by partnership in making decisions about treatment?" BMJ 319(7212): 780-782.
Clifford, D. B., A. De Luca, et al. (2010). "Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases." Lancet Neurol 9(4): 438-446.
Cohen, J. A., F. Barkhof, et al. (2010). "Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis." N Engl J Med 362(5): 402-415.
Comi, G., M. Filippi, et al. (2001). "Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study." Lancet 357(9268): 1576-1582.
Compston, A. and A. Coles (2002). "Multiple sclerosis." Lancet 359(9313): 1221-1231.
Confavreux, C., P. Saddier, et al. (1996). "Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study." Neurology 46(6): 1607-1612.
Confavreux, C. and S. Vukusic (2006). "Age at disability milestones in multiple sclerosis." Brain 129(Pt 3): 595-605.
Confavreux, C. and S. Vukusic (2006). "[The natural history of multiple sclerosis]."
Rev Prat 56(12): 1313-1320.
Confavreux, C., S. Vukusic, et al. (2003). "Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process." Brain 126(Pt 4): 770-782.
Coulter, E. J., Swain D, et al. (2006). Assessing the quality of information to support people in making decisions about their health and healthcare. Oxford, Picker Institute Europe, Oxford.
de Boer, v. L. J., Stalmeier PF, van Sandick JW, Hulscher JB, de Haes JC, Sprangers MA (2004). "„Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?”."
Qual Life Res. 13(2): 311-320.
Ebers, G. C. and M. Daumer (2008). "Natural history of MS." Eur J Neurol 15(9): 881-882.
Ebers GC, S. A. (1993). "The geographic distribution of multiple sclerosis: a review."
Neuroepidemiology 12: 1-5.
Ende, J., L. Kazis, et al. (1989). "Measuring patients' desire for autonomy: decision making and information-seeking preferences among medical patients." J Gen Intern Med 4(1): 23-30.
European Charta of Patients´ Rights. (2002). "European Charta of Patients´ Rights."
from http://www.activecitizenship.net/health/european_charter.pdf.
Feldman-Stewart, D., S. Brennenstuhl, et al. (2007). "A systematic review of information in decision aids." Health Expect 10(1): 46-61.
Feldman-Stewart, D., M. D. Brundage, et al. (2006). "A randomized controlled trial comparing two educational booklets on prostate cancer." Can J Urol 13(6):
3321-3326.
Filippini, G., F. Brusaferri, et al. (2000). "Corticosteroids or ACTH for acute exacerbations in multiple sclerosis." Cochrane Database Syst Rev(4):
CD001331.
Gaudry, E. and C. D. Spielberger (1970). "Anxiety and intelligence in paired-associate learning." J Educ Psychol 61(5): 386-391.
Ghalie, R. G., G. Edan, et al. (2002). "Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS." Neurology 59(6):
909-913.
Giovannoni, G., G. Comi, et al. (2010). "A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis." N Engl J Med 362(5): 416-426.
Gold, R. (2007). "Fortschritte im Verständnis von Pathogenese und Immuntherapie der Multiplen Sklerose." Nervenarzt 78: 15-26.
Grauer, O., M. Offenhausser, et al. (2001). "[Glucocorticosteroid therapy in optic neuritis and multiple sclerosis. Evidence from clinical studies and practical recommendations]." Nervenarzt 72(8): 577-589.
Hamann, J., B. Langer, et al. (2004). "[Shared decision making--from a model project towards implementation]." Z Arztl Fortbild Qualitatssich 98(2): 115-119.
Hamann, J., A. Loh, et al. (2006). "[Effects of a shared decision making model in psychiatric and neurologic practice]." Nervenarzt 77(9): 1071-1076, 1078.
Hamann, J., B. Neuner, et al. (2007). "Participation preferences of patients with acute and chronic conditions." Health Expect 10(4): 358-363.
Hartung, H. P., R. Gonsette, et al. (2002). "Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial."
Lancet 360(9350): 2018-2025.
Hawkins, S. A. and G. V. McDonnell (1999). "Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors." J Neurol Neurosurg Psychiatry 67(2): 148-152.
Heesen, C., J. Kasper, et al. (2007). "Informed shared decision making in multiple sclerosis--inevitable or impossible?" J Neurol Sci 259(1-2): 109-117.
Heesen, C., J. Kasper, et al. (2004). "Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis." Mult Scler 10(6):
643-650.
Heesen, C., J. Kolbeck, et al. (2003). "Delivering the diagnosis of MS--results of a survey among patients and neurologists." Acta Neurol Scand 107(5): 363-368.
Heesen, C., J. Segal, et al. (2006). "Patient information on cognitive symptoms in multiple sclerosis - acceptability in relation to disease duration." Acta Neurol Scand 114(4): 268-272.
Hein, H. (2000). "Hochrechnung der Zahl der an Multiple Sklerose erkrankten Patienten in Deutschland." Nervenarzt 71: 288-294.
Jacobs, L. D., R. W. Beck, et al. (2000). "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group." N Engl J Med 343(13): 898-904.
Johnson, K. P., B. R. Brooks, et al. (1995). "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group." Neurology 45(7): 1268-1276.
Joosten, E., G. de Weert, et al. (2008). "Effect of shared decision-making on
therapeutic alliance in addiction health care." Patient Prefer Adherence 2: 277-285.
Jorgensen, K. J. and P. C. Gotzsche (2004). "Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study."
BMJ 328(7432): 148.
Jorgensen, M. and F. C. Krebs (2004). "Stepwise and directional synthesis of end-functionalized single-oligomer OPVs and their application in organic solar cells." J Org Chem 69(20): 6688-6696.
Kalso, E., J. Edwards, et al. (2001). "Five easy pieces on evidence-based medicine (3)." Eur J Pain 5(2): 227-230.
Kappos, L., M. S. Freedman, et al. (2007). "Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study." Lancet
370(9585): 389-397.
Kappos, L., E. W. Radue, et al. (2010). "A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis." N Engl J Med 362(5): 387-401.
Kasper, J., C. Heesen, et al. (2009). "[Evidence-based patient information: the example of immunotherapy for patients with multiple sclerosis]."
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 52(1): 77-85.
Kasper, J., S. Kopke, et al. (2006). "Evidence-based patient information about treatment of multiple sclerosis--a phase one study on comprehension and emotional responses." Patient Educ Couns 62(1): 56-63.
Kasper, J., S. Kopke, et al. (2008). "Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial." Eur J Neurol 15(12): 1345-1352.
Keegan, M., F. Konig, et al. (2005). "Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange." Lancet 366(9485): 579-582.
Klug-Redman, B., Ed. (1996). Patientenschulung und –beratung. Berlin, Ullstein Mosby-. Berlin, Ullstein Mosby.
Koch, M. I. (2008). "Kriterien zur Erstellung von Patienteninformationen zu Krebsfrüherkennungsuntersuchungen. Stellungnahme des Fachbereichs Patienteninformation des Deutschen Netzwerkes für evidenzbasierte Medizin."
from http://www.ebmnetzwerk.de/.
Kopke, S., J. Kasper, et al. (2009). "Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial." Mult Scler 15(1): 96-104.
Kurtzke, J. F. (1983). "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)." Neurology 33(11): 1444-1452.
Kurtzke, J. F. (1993). "Epidemiologic evidence for multiple sclerosis as an infection."
Clin Microbiol Rev 6(4): 382-427.
Kurtzke, J. F. (2000). "Natural history and clinical outcome measures for multiple sclerosis studies. Why at the present time does EDSS scale remain a
preferred outcome measure to evaluate disease evolution?" Neurol Sci 21(6):
339-341.
Lublin, F. D. and S. C. Reingold (1996). "Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple
Sclerosis." Neurology 46(4): 907-911.
Marteau, B. (1992). "The development of a six-item short-form of the state scale of the Spielberger State–Trait Anxiety Inventory (STAI). ." Br J Clin Psychol. 31:
301-306.
McDonald, W. I., A. Compston, et al. (2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis." Ann Neurol 50(1): 121-127.
Meier-Gantenbein, K. F., Späth, T., Ed. (2006). „Hanbuch Bildung, Training und Beratung – Zehn Konzepte der professionellen Erwachsenenbildung“.
Weinheim und Basel, Beltz Verlag.
Meyer, G., A. Steckelberg, et al. (2007). "Analysis of consumer information brochures on osteoporosis prevention and treatment." Ger Med Sci 5: Doc01.
Milligan, N. M., R. Newcombe, et al. (1987). "A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects."
J Neurol Neurosurg Psychiatry 50(5): 511-516.
Mohr DC, G. D., Likosky W, Gatto N, Neilley LK, Griffin C, Stiebling B (1996).
"Therapeutic expectations of patients with multiple scle¬rosis upon initiating interferon-beta 1-b: relationship to adherence to treatment." Mult Scler 5: 222-226 and 107(225):363–368.
Mühlhauser, L. (2008). "Verbesserung der Therapieergebnisse durch
Patientenwissen? ." Z Evid Fortbild Qual Gesundheitswesen (ZEFQ) 102: 223-230.
Munari, L., R. Lovati, et al. (2004). "Therapy with glatiramer acetate for multiple sclerosis." Cochrane Database Syst Rev(1): CD004678.
Noseworthy, J. H., G. C. Ebers, et al. (1994). "The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial." Neurology 44(1): 16-20.
Oliveri, R. L., P. Valentino, et al. (1998). "Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study." Neurology 50(6): 1833-1836.
Omenn, G. S., G. Goodman, et al. (1994). "The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations:
smokers and asbestos-exposed workers." Cancer Res 54(7 Suppl): 2038s-2043s.
Oschmann P, A. D. (2006). "Von der Versorgungsforschung zur integri¬erten Versorgung am Beispiel der Multiplen Sklerose." Das Krankenhaus 5: 402-407.
Petermann, F., Ed. (1997). „Patientenschulung und Patientenberatung-Ein Lehrbuch“, Horgrefe-Verlag für Psychologie
Pittock, S. J., R. L. McClelland, et al. (2004). "Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study." Ann Neurol 56(2): 303-306.
Pittock, S. J. and M. Rodriguez (2008). "Benign multiple sclerosis: a distinct clinical entity with therapeutic implications." Curr Top Microbiol Immunol 318: 1-17.
Polman, C. H., P. W. O'Connor, et al. (2006). "A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis." N Engl J Med 354(9): 899-910.
Polman, C. H., S. C. Reingold, et al. (2011). "Diagnostic criteria for multiple sclerosis:
2010 revisions to the McDonald criteria." Ann Neurol 69(2): 292-302.
Polman, C. H., S. C. Reingold, et al. (2005). "Diagnostic criteria for multiple sclerosis:
2005 revisions to the "McDonald Criteria"." Ann Neurol 58(6): 840-846.
Poser, P. D., Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983). "New diagnostic criteria for multiple sclerosis: guidelines for research protocols." Ann Neurol Sci 13: 227 -231.
Richards, R. G., F. C. Sampson, et al. (2002). "A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models." Health Technol Assess 6(10): 1-73.
Rieckmann, P. (2006). "[Escalating immunomodulatory therapy of multiple sclerosis.
Update (September 2006)]." Nervenarzt 77(12): 1506-1518.
Rudick, R. A., D. Miller, et al. (2007). "Health-related quality of life in multiple sclerosis: effects of natalizumab." Ann Neurol 62(4): 335-346.
Rudick, R. A., W. H. Stuart, et al. (2006). "Natalizumab plus interferon beta-1a for relapsing multiple sclerosis." N Engl J Med 354(9): 911-923.
Ruprecht, K., E. Klinker, et al. (2004). "Plasma exchange for severe optic neuritis:
treatment of 10 patients." Neurology 63(6): 1081-1083.
Sackett, D. L., W. M. Rosenberg, et al. (1996). "Evidence based medicine: what it is and what it isn't." BMJ 312(7023): 71-72.
Sackett, K., C. Hendricks, et al. (2000). "Collaboration: an innovative education/business partnership." Case Manager 11(6): 40-44.
Sämann, M. I., Bender R, Kloos Ch, Müller UA (2005). Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable
dietary freedom in people with type 1 diabetes: prospective implementation study. Diabetologia.
Schilling, S., R. A. Linker, et al. (2006). "[Plasma exchange therapy for
steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients]."
Nervenarzt 77(4): 430-438.
Schumacher, B. G., Kibler RF, Kurland LT, Kurtzke JF, McDowell F, Nagler B, Sibley WA, Tourtellotte WW, Willmon TL (1965). "Problems of experimental trials of therapy in Multiple Sclerosis: Report by the panel of the evaluation of
experimental trials of therapy in Multiple Sclerosis." Annals NY Acad Sci 122:
552-558
Sellebjerg, F., J. L. Frederiksen, et al. (1998). "Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS."
Neurology 51(2): 529-534.
Simeoni, M., P. Auquier, et al. (2008). "Validation of the Multiple Sclerosis International Quality of Life questionnaire." Mult Scler 14(2): 219-230.
Sospedra, M. and R. Martin (2005). "Immunology of multiple sclerosis." Annu Rev Immunol 23: 683-747.
Squyres, W. D. (1980). "Inquiry into action: what are the next steps?" Springer Ser Health Care Soc 4: 299-301.
Steckelberg, A., B. Berger, et al. (2005). "[Criteria for evidence-based patient information]." Z Arztl Fortbild Qualitatssich 99(6): 343-351.
Trevena, L. J., H. M. Davey, et al. (2006). "A systematic review on communicating with patients about evidence." J Eval Clin Pract 12(1): 13-23.
Trojano, M., D. Paolicelli, et al. (2003). "The transition from relapsing-remitting MS to irreversible disability: clinical evaluation." Neurol Sci 24 Suppl 5: S268-270.
Weinshenker, B. G., P. C. O'Brien, et al. (1999). "A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease." Ann Neurol 46(6): 878-886.
!
!
!
!
!
!